Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...

Tempus announced its acquisition of Ambry Genetics for $375 million in cash ... Ambry served as Tempus' largest reference laboratory for hereditary cancer screening, and the companies had entered ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. Tempus is a technology ...

CHICAGO, February 03, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has ...

Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc. “They’ve achieved one of the rare things in our space where you actually have ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Tempus AI announced today it is acquiring genetic ...

Ambry Genetics performs all hereditary cancer tests in its CAP-accredited, CLIA-certified and New York State approved laboratory. For more information about the updated menu, please visit Ambry ...

Ambry Genetics performs all hereditary cancer tests in its CAP-accredited, CLIA-certified and New York State approved laboratory. For more information about the updated menu, please visit Ambry’s ...